Connect to other sites within the UBM Medica Network
One-Step Screening Tool Identifies Patients Needing Palliative Care
Researchers have developed a screening tool to help oncology providers identify cancer patients who may benefit from referral to a palliative care specialist.
Current Guidelines Miss One-Third of RCC Recurrences
If physicians are following the current NCCN and AUA renal cell carcinoma surveillance guidelines, they could be missing as many as one-third of recurrences.
Non-GCB DLBCL May Benefit Most From Immunochemotherapy
Non-germinal center B-cell-like DLBCL patients derived the most benefit from treatment with the immunochemotherapy regimen R-ACVBP compared with R-CHOP.
Amgen Halts Rilotumumab Development Due to Increased Death Signal
Amgen has halted clinical trials of rilotumumab in gastric cancer after a planned safety review showed an increase in the risk of death with the study drug.
Risk of Second Cancers Among Current Smokers
This slide show reports on a pooled analysis that found up to a fivefold risk of second cancers among smokers, compared with cancer survivors who never smoked.
Smoking May Increase Risk of Second Primary Cancer
Cancer survivors are at an increased risk for developing a second smoking-associated cancer if they smoked cigarettes prior to their first cancer diagnosis.
High BMI and Obesity Linked to Half a Million New Cancer Cases Annually
Researchers are estimating that about 3.6% of new cancer cases in 2012 in adults may be attributed to a high BMI, equating to about 481,000 new cancer cases.
Survey Highlights Gaps in Cervical Cancer Screening Rates
More than 11% of all eligible women had not been screened for cervical cancer in the past 5 years, according to a study by researchers at the CDC.
Virus May Be Active Against Advanced Ovarian Cancer
An oncolytic herpes simplex virus had significant efficacy against ovarian cancer when used alone and in combination with standard chemotherapy treatment.
Extended Rituximab Plus R-CHOP Best in Elderly, Poor-Prognosis DLBCL
Elderly patients with poor-prognosis DLBCL may derive the most benefit from treatment with extended rituximab plus 6 cycles of R-CHOP on a 14-day schedule.
By clicking Accept, you agree to become a member of the UBM Medica Community.